MOTS-c: Complete Guide to the Mitochondrial-Derived Peptide

In the 2015 discovery work, MOTS-c acted primarily on skeletal muscle. Inside cells it inhibited the folate cycle and the de novo purine synthesis tethered to it, which led to an accumulation of AICAR, an endogenous metabolite that activates AMP-activated protein kinase (AMPK), the cell's central energy sensor.^[1]

A 2018 study added a second layer. Under metabolic stress such as glucose restriction, MOTS-c moved into the nucleus in an AMPK-dependent manner, regulated a broad set of nuclear genes, including genes with antioxidant response elements, and interacted with stress-responsive transcription factors such as NRF2. The authors presented this as evidence that the mitochondrial genome encodes factors that regulate the nucleus.^[2]

These mechanisms were mapped in cultured cells and mice. They explain why reviews describe MOTS-c as an exercise mimetic, but they do not show that the same pathway operates at a meaningful scale when the peptide is given to people.^[4]

In mice, MOTS-c treatment prevented both age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. The same paper reported that MOTS-c levels in mouse skeletal muscle and circulation declined as insulin resistance developed with age.^[1]

A 2021 study in Nature Communications extended the work to physical capacity. MOTS-c treatment improved physical performance in young (2 months), middle-aged (12 months) and old (22 months) mice, and intermittent treatment started late in life, at 23.5 months, increased physical capacity and healthspan measures.^[3]

Lifespan itself is less clear. A 2022 review noted that the late-life treatment produced a trend toward longer lifespan that did not reach statistical significance, possibly because of suboptimal dosing and the short half-life of circulating MOTS-c, even though grip strength, gait and physical performance improved.^[4][3]

The human data are observational and small. In 10 sedentary young men, a bout of cycling raised MOTS-c about 11.9-fold in skeletal muscle and about 1.5- to 1.6-fold in plasma, with plasma levels back to baseline after four hours of rest. A separate randomised study of acute exercise found only a trend towards higher plasma MOTS-c after endurance exercise.^[3][9]

With age, circulating MOTS-c appears to fall while skeletal-muscle expression rises: older and middle-aged men had about 1.5-fold higher muscle MOTS-c than young men. In obesity and diabetes the picture is inconsistent. One small study found similar plasma levels in lean and obese adults, another found higher levels in adults with obesity that did not change after bariatric surgery, and a 2024 meta-analysis of seven studies found lower levels in type 2 diabetes but higher levels in obesity.^{[8][10][11][12]}

Part of that inconsistency may be analytical. When an anti-doping laboratory built a mass-spectrometry assay for MOTS-c, it could not confirm the endogenous plasma levels that a commercial ELISA reported in 20 healthy volunteers, and the two methods gave considerably different values.^[13]

Genetics offers indirect human evidence. An Asian-specific mitochondrial DNA variant, m.1382A>C, changes one amino acid of MOTS-c (K14Q). In a meta-analysis of three cohorts totalling 27,527 people, men carrying the C allele had a higher prevalence of type 2 diabetes, and in one cohort the effect was confined to men in the lowest third of physical activity; women were unaffected.^[6]

In the same work, high-fat-fed male mice given standard MOTS-c gained less weight and had better glucose tolerance, while mice given the K14Q form did not, and the variant peptide was less insulin-sensitising in cells. Earlier, a 2015 paper had proposed that the variant might be among the mechanisms behind the high longevity of Japanese people. That remains a hypothesis, not a finding.^[6][7]

The clinical record is thin. A MOTS-c analogue, CB4211, completed a randomised phase 1a/1b study of safety, tolerability and pharmacokinetics in healthy non-obese volunteers and in people with non-alcoholic fatty liver disease. The ClinicalTrials.gov record lists 88 participants, a primary completion date in April 2021 and no posted results; reviews describe the analogue as having entered trials for fatty liver disease and obesity.^[14][4][5]

In 2026, a randomised, placebo-controlled phase 2a trial of MOTS-c itself began recruiting adults with prediabetes and overweight or obesity. It plans to enrol about 120 people for 12 weeks of treatment, with change in insulin sensitivity (the Matsuda index) and adverse events as primary outcomes, and an estimated primary completion date in 2027.^[15]

Until trials like these report, claims about what MOTS-c does in people have no controlled-trial support, and no human safety profile has been established for the native peptide.^[15][14]

Both are filed under mitochondrial research, but they are different kinds of molecule. MOTS-c is a peptide signal encoded by mitochondrial DNA; in cell and mouse studies it works through AMPK activation and, under stress, through nuclear gene regulation.^[1][2]

NAD+ is not a peptide at all but a coenzyme that cells consume and regenerate, so research on it asks about supply rather than signalling. Our NAD+ guide covers that biology with its own sources, and the comparison page sets the two side by side.

MOTS-c is named on the World Anti-Doping Agency's 2026 Prohibited List. It appears under S4.4 Metabolic modulators as an example of an activator of AMP-activated protein kinase, alongside AICAR, in a class that is prohibited at all times, in and out of competition.^[16]

Anti-doping laboratories have had a detection method for some time: a mass-spectrometry assay for MOTS-c in plasma was developed and validated in 2019 according to WADA's International Standard for Laboratories.^[13]

MOTS-c is not an authorised medicine in the EU. The European Medicines Agency's database of authorised medicines lists no MOTS-c product as of September 2026.^[17]

Peptyds supplies MOTS-c as a lyophilised research peptide for in-vitro laboratory work, with batch documentation described on the quality page. It is not a supplement or a medicine, and it is not supplied for human or veterinary use.

The honest summary is a genuinely interesting mitochondria-derived peptide with a defined mechanism in cells, consistent effects in mice, small and inconsistent observational data in people, one analogue through phase 1 without posted results, and a first phase 2a trial under way. Claims about fat loss, energy or longevity in people are ahead of that evidence.^{[1][3][12][14][15]}